Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.

Erasca (ERAS) has been in focus after updated preliminary Phase 1 data for ERAS-0015 in RAS-mutant solid tumors, including pancreatic cancer, coincided with a sizeable follow-on equity offering and a sharp move in the stock.

See our latest analysis for Erasca.

The latest ERAS-0015 update and follow-on offering sit against a powerful run in Erasca's stock, with a 1-day share price return of 8.94%, a 30-day share price return of 38.79%, and a year-to-date share price return of 443.18%. The 1-year total shareholder return is very large, suggesting momentum in investor expectations around both growth prospects and risk.

If this kind of clinical and fundraising activity has your attention, it can be useful to widen the lens and see what other oncology and biotech companies are doing with AI. One way to do that is by checking out 40 healthcare AI stocks

After Erasca's sharp move and a last close of $19.50 versus an average analyst target of $21.90, the spread between price and published estimates is tight. Where might a reasonable view of fair value sit now?

Preferred Price-to-Book Multiple of 15.4x: Is It Justified?

With Erasca trading at a last close of $19.50 and a tight gap to the average analyst target, the P/B ratio of 15.4x stands out as a key valuation reference point against both its closest peers and the broader US biotech industry.

The price-to-book ratio compares Erasca's market value to its book value, which is essentially net assets on the balance sheet. For a clinical-stage biotech with no revenue and sizeable reported losses of $277.02m, investors often focus on P/B as a shorthand for how the market is valuing the company's pipeline, intellectual property, and future potential rather than current earnings.

On one hand, Erasca is described as good value against its peer group average P/B of 18.4x, which suggests the stock is trading at a lower premium than some close comparables. On the other hand, when lined up against the broader US Biotechs industry average of 2.6x, Erasca's 15.4x P/B is much higher. That contrast points to a valuation that is significantly richer than the typical biotech stock, even if it looks relatively restrained within a narrower peer set where expectations may also be elevated.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-book of 15.4x (ABOUT RIGHT)